Recro Pharma Inc (NASDAQ:REPH) Sees Large Growth in Short Interest

Share on StockTwits

Recro Pharma Inc (NASDAQ:REPH) was the recipient of a significant growth in short interest in November. As of November 29th, there was short interest totalling 1,260,000 shares, a growth of 17.8% from the November 14th total of 1,070,000 shares. Based on an average daily volume of 269,500 shares, the short-interest ratio is currently 4.7 days. Approximately 6.5% of the company’s stock are short sold.

REPH traded up $0.06 on Friday, reaching $16.81. 354,870 shares of the company traded hands, compared to its average volume of 299,062. The stock’s 50 day moving average price is $16.02 and its 200-day moving average price is $12.03. Recro Pharma has a 52-week low of $5.53 and a 52-week high of $18.20.

Recro Pharma (NASDAQ:REPH) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.06). The business had revenue of $25.26 million for the quarter, compared to analysts’ expectations of $19.83 million. On average, equities analysts forecast that Recro Pharma will post -0.6 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its stake in Recro Pharma by 635.8% in the third quarter. Tower Research Capital LLC TRC now owns 2,943 shares of the specialty pharmaceutical company’s stock valued at $33,000 after acquiring an additional 2,543 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Recro Pharma in the second quarter valued at approximately $48,000. Metropolitan Life Insurance Co NY acquired a new stake in Recro Pharma in the third quarter valued at approximately $84,000. Paloma Partners Management Co acquired a new stake in Recro Pharma in the second quarter valued at approximately $109,000. Finally, Meeder Asset Management Inc. lifted its stake in Recro Pharma by 153.5% in the second quarter. Meeder Asset Management Inc. now owns 12,895 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 7,809 shares during the last quarter. Hedge funds and other institutional investors own 59.30% of the company’s stock.

A number of research analysts recently commented on the stock. ValuEngine downgraded shares of Recro Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd. Stephens lowered their price objective on shares of Recro Pharma from $23.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 26th. BidaskClub raised shares of Recro Pharma from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Wednesday, October 30th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $14.90.

About Recro Pharma

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Read More: Blue-Chip Stocks

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Founders Capital Management Sells 500 Shares of Weingarten Realty Investors
Founders Capital Management Sells 500 Shares of Weingarten Realty Investors
Founders Capital Management Has $28,000 Stock Holdings in Genworth Financial Inc
Founders Capital Management Has $28,000 Stock Holdings in Genworth Financial Inc
Comcast Co.  Stake Boosted by 10 15 Associates Inc.
Comcast Co. Stake Boosted by 10 15 Associates Inc.
10 15 Associates Inc. Has $2.27 Million Stake in Air Products & Chemicals, Inc.
10 15 Associates Inc. Has $2.27 Million Stake in Air Products & Chemicals, Inc.
10 15 Associates Inc. Has $2.86 Million Stock Holdings in CVS Health Corp
10 15 Associates Inc. Has $2.86 Million Stock Holdings in CVS Health Corp
10 15 Associates Inc. Grows Stock Holdings in Canadian Pacific Railway Ltd
10 15 Associates Inc. Grows Stock Holdings in Canadian Pacific Railway Ltd


© 2006-2020 Ticker Report